Boston, MA 07/12/2013 (wallstreetpr) – Shares of biotechnology companies have been recording significant gains for the past few trading sessions. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), with a primary focus on the development and commercialization of drugs aimed at blocking the enzymes involved in the pathogenesis of diseases, has recently been experiencing significant surges supported by huge trading volumes. A recent pharmaceutical sector report published by the Global Market Direct presented a complete overview on the future prospects of BCRX. The company’s focus on research and development, latest updates, progress of the drugs that are in the pipeline, as well as other news on dormant or dropped drugs, have all been discussed in detail in the report.
The principal product candidate of the biotechnology company is Peramivir, which is used as a neuraminidase inhibitor for the treatment of patients infected with influenza. Furthermore, BCRX has other products which are in the development stages such as two inhibitors of purine nucleoside phosphorylase. The two inhibitors include BCX4208, which is aimed towards the treatment of gout, and forodesine, which is aimed at the treatment of hematological malignancies.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) closed at $1.82 on Thursday, recording an increase of 11.66% in its share price for the day. The stock price fluctuated from a low value of $1.68 to a high one of $1.88 per share. The company currently has a 52-week low of $1.08 and a 52-week high of $4.95 per share. BioCryst currently has 53.15 million outstanding shares in the market with institutional ownership of 32% of the total equity capital. Trading volume for the stock amounted to 1.67 million shares on Thursday; with an average one for BioCryst at 814,095.00 shares per day.
